Global Cord Bank StemCyte operates the world’s largest public cord blood bank with over 36,000 units and has a global footprint spanning the United States and Taiwan, presenting a broad potential for cross-border cord blood sourcing, partnerships, and international clinical collaborations.

FDA Biologics Milestone In November 2024 StemCyte became the first private company to receive FDA approval for a cord blood biologics license, signaling validated product safety and potential for increased adoption, enabling sales conversations with hospitals and transplant centers seeking approved cord blood therapies.

Private Public Synergy StemCyte uniquely operates both public and private cord blood banks, creating dual-channel value propositions for institutions and patients, and opening cross-sell opportunities to healthcare providers managing diverse donor and patient needs.

Strategic Partnerships Recent alliances in Taiwan with Taishin Life for Public Bank Matching Protection Service demonstrate a pathway for insurance-enabled access and risk mitigation, suggesting opportunities to expand partnerships with insurers and healthcare providers on a regional basis.

Growing Demand With a revenue range of 50 to 100 million and ongoing expansion in mature markets, StemCyte’s proven track record of supplying cord blood units to 350 transplant centers indicates strong demand signals for expanded product offerings, service add-ons, and tiered pricing tailored to hospital networks.